#United States #New York #Securities Class Action #Faruqi & Faruqi #Aquestive Therapeutics

Alert for Aquestive Therapeutics Investors

In a significant reminder for investors, Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued an important notice pertaining to Aquestive Therapeutics, Inc. (NASDAQ: AQST). Investors who suffered financial losses during a specific timeframe are encouraged to take action before an impending deadline.

Background

The firm is actively investigating claims against Aquestive Therapeutics, particularly focusing on issues arising from securities class action lawsuits. Investors who purchased XX shares from June 16, 2025, to January 8, 2026, could be eligible to share in any potential recovery due to the upcoming legal proceedings.

Historically, Aquestive Therapeutics has faced scrutiny for various reasons, including the handling of its New Drug Application (NDA) for Anaphylm—a medication meant to address severe allergic reactions. Recent communications revealed deficiencies identified by the FDA that obstruct the company from discussing pivotal aspects such as labeling and post-marketing commitments for Anaphylm.

This is particularly critical as the lack of transparency around these FDA findings has led to significant drops in share value, causing distress among investors. After the announcement from the CEO regarding the NDA issues, the share price plummeted by 37.04%, closing at $3.91 per share, highlighting the steep declines that can occur in reaction to regulatory decisions.

Legal Ramifications

Faruqi & Faruqi emphasizes the importance of understanding your rights as an investor and the legal options available. The firm invites individuals who have been affected to reach out and discuss potential actions regarding their investments in Aquestive. Interested parties must act swiftly, as the deadline to seek the role of lead plaintiff in the federal securities class action is set for May 4, 2026.

The lead plaintiff, an appointed representative whose financial position aligns with the class, holds an essential role in directing the proceedings on behalf of the affected investors. Anyone wishing to learn more about their rights or seeking guidance on becoming a lead plaintiff should contact Faruqi & Faruqi directly.

Take Action

As part of their ongoing mission to safeguard investor rights, Faruqi & Faruqi also encourages whistleblowers, past employees, and shareholders with information relating to Aquestive's situation to make contact. Such engagement can provide crucial insights during the investigation and potential proceedings.

Investors can find the necessary information and resources on the law firm’s official website, where further details on the class action are also provided. The firm’s team of experienced attorneys is available to assist and answer any questions regarding the various legal processes that may unfold.

Faruqi & Faruqi has built a reputation for effectively representing investors and has recovered substantial sums over the years. They remain vigilant in their commitment to advocate on behalf of those affected by insufficient corporate disclosures and misleading information.

Stay updated by following Faruqi & Faruqi on their social media platforms, including LinkedIn, X, and Facebook, where they share ongoing developments and additional insights.

Conclusion

As the May deadline approaches, affected investors should leverage the opportunity to participate actively in the class action lawsuit against Aquestive Therapeutics. For direct inquiries or assistance, reaching out to Faruqi & Faruqi can help navigate the complexities of securities law effectively.

For further assistance, potential participants are encouraged to call Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).